The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive Review. (PubMed, Reports (MDPI)) - Sep 25, 2026 - " These cases illustrate that inclisiran can effectively lower LDL-C levels across primary and secondary prevention settings in PWH facing oral therapy limitations or statin intolerance. Provider-administered dosing every 6 months overcomes adherence challenges, supporting the inclusion of PWH in broader clinical pathways pending ongoing cardiovascular outcome trials."
Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Myocardial Infarction • CD4
|
|
Anastasia Grapsa; Andreas G Tsantes; Maria Panopoulou; Periklis Panagopoulos; Vasileios Petrakis
|